263 related articles for article (PubMed ID: 25994549)
21. Phase I/II trial of a replication-deficient trivalent influenza virus vaccine lacking NS1.
Mössler C; Groiss F; Wolzt M; Wolschek M; Seipelt J; Muster T
Vaccine; 2013 Dec; 31(52):6194-200. PubMed ID: 24183981
[TBL] [Abstract][Full Text] [Related]
22. Genetic stability of live attenuated vaccines against potentially pandemic influenza viruses.
Kiseleva I; Dubrovina I; Fedorova E; Larionova N; Isakova-Sivak I; Bazhenova E; Pisareva M; Kuznetsova V; Flores J; Rudenko L
Vaccine; 2015 Dec; 33(49):7008-14. PubMed ID: 26432909
[TBL] [Abstract][Full Text] [Related]
23. A novel peptide-based pan-influenza A vaccine: a double blind, randomised clinical trial of immunogenicity and safety.
Francis JN; Bunce CJ; Horlock C; Watson JM; Warrington SJ; Georges B; Brown CB
Vaccine; 2015 Jan; 33(2):396-402. PubMed ID: 24928790
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.
Frey SE; Bernstein DI; Brady RC; Keitel WA; El Sahly H; Rouphael NG; Mulligan MJ; Atmar RL; Edupuganti S; Patel SM; Dickey M; Graham I; Anderson EL; Noah DL; Hill H; Wolff M; Belshe RB
Vaccine; 2015 Jan; 33(1):163-73. PubMed ID: 25444805
[TBL] [Abstract][Full Text] [Related]
25. Shedding of Ann Arbor strain live attenuated influenza vaccine virus in children 6-59 months of age.
Mallory RM; Yi T; Ambrose CS
Vaccine; 2011 Jun; 29(26):4322-7. PubMed ID: 21513761
[TBL] [Abstract][Full Text] [Related]
26. Improved immunogenicity with high-dose seasonal influenza vaccine in HIV-infected persons: a single-center, parallel, randomized trial.
McKittrick N; Frank I; Jacobson JM; White CJ; Kim D; Kappes R; DiGiorgio C; Kenney T; Boyer J; Tebas P
Ann Intern Med; 2013 Jan; 158(1):19-26. PubMed ID: 23277897
[TBL] [Abstract][Full Text] [Related]
27. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans.
Lillie PJ; Berthoud TK; Powell TJ; Lambe T; Mullarkey C; Spencer AJ; Hamill M; Peng Y; Blais ME; Duncan CJ; Sheehy SH; Havelock T; Faust SN; Williams RL; Gilbert A; Oxford J; Dong T; Hill AV; Gilbert SC
Clin Infect Dis; 2012 Jul; 55(1):19-25. PubMed ID: 22441650
[TBL] [Abstract][Full Text] [Related]
28. A novel influenza A (H1N1) vaccine in various age groups.
Zhu FC; Wang H; Fang HH; Yang JG; Lin XJ; Liang XF; Zhang XF; Pan HX; Meng FY; Hu YM; Liu WD; Li CG; Li W; Zhang X; Hu JM; Peng WB; Yang BP; Xi P; Wang HQ; Zheng JS
N Engl J Med; 2009 Dec; 361(25):2414-23. PubMed ID: 19846844
[TBL] [Abstract][Full Text] [Related]
29. Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch.
Glenn GM; Thomas DN; Poffenberger KL; Flyer DC; Ellingsworth LR; Andersen BH; Frech SA
Vaccine; 2009 Dec; 27 Suppl 6():G60-6. PubMed ID: 20006142
[TBL] [Abstract][Full Text] [Related]
30. The Madin-Darby canine kidney cell culture derived influenza A/H5N1 vaccine: a phase I trial in Taiwan.
Pan SC; Kung HC; Kao TM; Wu H; Dong SX; Hu MH; Chou AH; Chong P; Hsieh SM; Chang SC
J Microbiol Immunol Infect; 2013 Dec; 46(6):448-55. PubMed ID: 23022464
[TBL] [Abstract][Full Text] [Related]
31. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
[TBL] [Abstract][Full Text] [Related]
32. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial.
Liang XF; Wang HQ; Wang JZ; Fang HH; Wu J; Zhu FC; Li RC; Xia SL; Zhao YL; Li FJ; Yan SH; Yin WD; An K; Feng DJ; Cui XL; Qi FC; Ju CJ; Zhang YH; Guo ZJ; Chen PY; Chen Z; Yan KM; Wang Y
Lancet; 2010 Jan; 375(9708):56-66. PubMed ID: 20018364
[TBL] [Abstract][Full Text] [Related]
33. Accelerating Influenza Research: Vaccines, Antivirals, Immunomodulators and Monoclonal Antibodies. The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model.
Fullen DJ; Noulin N; Catchpole A; Fathi H; Murray EJ; Mann A; Eze K; Balaratnam G; Borley DW; Gilbert A; Lambkin-Williams R
PLoS One; 2016; 11(1):e0145902. PubMed ID: 26761707
[TBL] [Abstract][Full Text] [Related]
34. Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial.
Hung IF; Zhang AJ; To KK; Chan JF; Li P; Wong TL; Zhang R; Chan TC; Chan BC; Wai HH; Chan LW; Fong HP; Hui RK; Kong KL; Leung AC; Ngan AH; Tsang LW; Yeung AP; Yiu GC; Yung W; Lau JY; Chen H; Chan KH; Yuen KY
Lancet Infect Dis; 2016 Feb; 16(2):209-18. PubMed ID: 26559482
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial.
Madhi SA; Dittmer S; Kuwanda L; Venter M; Cassim H; Lazarus E; Thomas T; Liberty A; Treurnich F; Cutland CL; Weinberg A; Violari A
AIDS; 2013 Jan; 27(3):369-79. PubMed ID: 23032417
[TBL] [Abstract][Full Text] [Related]
36. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.
Levie K; Leroux-Roels I; Hoppenbrouwers K; Kervyn AD; Vandermeulen C; Forgus S; Leroux-Roels G; Pichon S; Kusters I
J Infect Dis; 2008 Sep; 198(5):642-9. PubMed ID: 18576945
[TBL] [Abstract][Full Text] [Related]
37. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
[TBL] [Abstract][Full Text] [Related]
38. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study.
Englund JA; Walter E; Black S; Blatter M; Nyberg J; Ruben FL; Decker MD;
Pediatr Infect Dis J; 2010 Feb; 29(2):105-10. PubMed ID: 19934787
[TBL] [Abstract][Full Text] [Related]
39. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.
Kreijtz JH; Goeijenbier M; Moesker FM; van den Dries L; Goeijenbier S; De Gruyter HL; Lehmann MH; Mutsert Gd; van de Vijver DA; Volz A; Fouchier RA; van Gorp EC; Rimmelzwaan GF; Sutter G; Osterhaus AD
Lancet Infect Dis; 2014 Dec; 14(12):1196-207. PubMed ID: 25455987
[TBL] [Abstract][Full Text] [Related]
40. Characterisation of a wild-type influenza (A/H1N1) virus strain as an experimental challenge agent in humans.
Watson JM; Francis JN; Mesens S; Faiman GA; Makin J; Patriarca P; Treanor JJ; Georges B; Bunce CJ
Virol J; 2015 Feb; 12():13. PubMed ID: 25645025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
